Spontaneous colitis occurrence in transgenic mice with altered B7-mediated costimulation

Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA.
The Journal of Immunology (Impact Factor: 4.92). 11/2008; 181(8):5278-88. DOI: 10.4049/jimmunol.181.8.5278
Source: PubMed


The B7 costimulatory molecules govern many aspects of T cell immune responses by interacting with CD28 for costimulation, but also with CTLA-4 for immune suppression. Although blockade of CTLA-4 with Ab in humans undergoing cancer immune therapy has led to some cases of inflammatory bowel disease, spontaneous animal models of colitis that depend upon modulation of B7 interactions have not been previously described. In this study, we demonstrate that mice expressing a soluble B7-2 Ig Fc chimeric protein spontaneously develop colitis that is dependent on CD28-mediated costimulation of CD4(+) T cells. We show that the chimeric protein has mixed agonistic/antagonist properties, and that it acts in part by blocking the cell intrinsic effects on T cell activation of engagement of CTLA-4. Disease occurred in transgenic mice that lack expression of the endogenous B7 molecules (B7 double knock-out mice), because of the relatively weak costimulatory delivered by the chimeric protein. Surprisingly, colitis was more severe in this context, which was associated with the decreased number of Foxp3(+) regulatory T cells in transgenic B7 double knock-out mice. This model provides an important tool for examining how B7 molecules and their effects on CTLA-4 modulate T cell function and the development of inflammatory diseases.

7 Reads
  • Source
    • "Moreover, deletion of B7 in mice expressing a soluble B7-2 Ig Fc chimeric protein resulted in more severe colitis with reduction of Tregs (Kim et al., 2008). Blockage of CTLA-4 by its antibody abrogated the effect of Tregs on prevention of colitis in vivo (Read et al., 2000; Takahashi et al., 2000). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic inflammation contributes to cancer development via multiple mechanisms. One potential mechanism is that chronic inflammation can generate an immunosuppressive microenvironment that allows advantages for tumor formation and progression. The immunosuppressive environment in certain chronic inflammatory diseases and solid cancers is characterized by accumulation of pro-inflammatory mediators, infiltration of immune suppressor cells, and activation of immune checkpoint pathways in effector T cells. In this review, we highlight recent advances in our understanding of how immunosuppression contributes to cancer and how pro-inflammatory mediators induce the immunosuppressive microenvironment via induction of immunosuppressive cells and activation of immune checkpoint pathways.
    Carcinogenesis 09/2015; 36(10). DOI:10.1093/carcin/bgv123 · 5.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The cells and tissues of the intestinal tract are subjected to a constant onslaught of antigenic challenge from both beneficial and harmful pathogens. Despite this constant stimulation, the host is able to maintain a relatively stable environment, often referred to as 'a controlled state of inflammation'. In patients with chronic inflammatory bowel disease, this controlled state of inflammation is lost. The cause of this loss of control is not fully understood, but there is emerging research interest in positive and negative costimulatory pathways as potential targets for modulating the dysregulation. This review describes the B7 and B7-like butyrophilin families of costimulatory molecules, with an emphasis on the role of costimulation in intestinal inflammation.
    Current opinion in investigational drugs (London, England: 2000) 06/2009; 10(5):443-51. · 3.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: RUNX3 was recently found to be associated with ulcerative colitis. In this study, downstream target genes of RUNX3 were identified by chromatin immunoprecipitation and promoter sequence microarray chips. Polymorphisms of RUNX3 and its 2 putative downstream (OCTN1 and PPAR-gamma) target genes were genotyped by PCR-SSP and sequencing in 144 Chinese UC patients and 151 healthy controls. Expression of RUNX3 in colonic mucosa of UC patients was detected by immunohistochemical staining. Twelve genes involved in IBD were identified as the downstream target genes of RUNX3. The RUNX3 rs2236851 CT genotype was associated significantly with UC susceptibility and risk of early onset in Chinese population. No association of OCTN1 and PPAR-gamma with UC susceptibility or subphenotypes was identified. RUNX3 expression was significantly increased in UC mucosa. Therefore, RUNX3 might be involved in UC pathogenesis by regulating the expression of genes related with immune response.
    Clinical Immunology 04/2010; 135(3):483-9. DOI:10.1016/j.clim.2010.01.004 · 3.67 Impact Factor
Show more


7 Reads
Available from